找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Human Tumour Xenografts in Anticancer Drug Development; Benjamin Winograd,Michael Peckham,Herbert Michael Conference proceedings 1988 Spr

[復(fù)制鏈接]
樓主: 浮淺
31#
發(fā)表于 2025-3-26 23:10:21 | 只看該作者
Biology of Human Ovarian Cancer Xenografts1% of all specimens could be transferred beyond 3 passages. Transplantability was most successful if samples were derived from a metastatic lesion, contained a high number of mitotic figures and were not infiltrated by lymphocytes. The take rate was not dependent on the histologic subtype or the deg
32#
發(fā)表于 2025-3-27 02:12:57 | 只看該作者
33#
發(fā)表于 2025-3-27 08:09:06 | 只看該作者
Comparison of Tumor Response in Nude Mice and in Patients obtained in 79%, rapid tumor growth after 3 months in 51%, and 49% of these tumors were transferred in serial passages. Most of the latter tumors were suitable for drug testing. In order to investigate whether tumor response in nude mice is consistent with patient response, 80 comparisons were perf
34#
發(fā)表于 2025-3-27 13:06:22 | 只看該作者
35#
發(fā)表于 2025-3-27 15:58:30 | 只看該作者
36#
發(fā)表于 2025-3-27 19:57:01 | 只看該作者
37#
發(fā)表于 2025-3-28 01:51:13 | 只看該作者
Lung Xenografts as a Predictive Screen for Antineoplastic Agentstumour categories and the various histological types. From the 131 tumours growing in primary transplants, 80 tumours could be established as lines. In order to examine whether growth characteristics of untreated tumours in nude mice might be of prognostic significance for patient survival, the data
38#
發(fā)表于 2025-3-28 02:43:58 | 只看該作者
Chemotherapy Studies in Human Non-Small Cell Lung Cancer Xenografts Transplanted in Immune-Deprived squamous carcinoma. The overall take rate of all tumour fragments implanted in the first man to mouse passage was low (10%) but this improved in subsequent passages to 57%. Growth rates were variable in all xenografts. Histopathological features were maintained through the first 7 passages although
39#
發(fā)表于 2025-3-28 06:32:02 | 只看該作者
40#
發(fā)表于 2025-3-28 13:05:36 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 13:38
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
定州市| 鹤峰县| 拉萨市| 驻马店市| 漠河县| 湾仔区| 临西县| 江华| 屯昌县| 正宁县| 高阳县| 宁波市| 房山区| 平南县| 富锦市| 白河县| 增城市| 通榆县| 秀山| 龙岩市| 温泉县| 莱芜市| 江城| 正镶白旗| 兴文县| 绥滨县| 团风县| 盐池县| 宝丰县| 拉孜县| 纳雍县| 称多县| 黑龙江省| 来宾市| 麻阳| 阳朔县| 科技| 突泉县| 内丘县| 工布江达县| 如皋市|